Top 10 Healthcare Companies by Revenue in 2025

By -
Here are the top 10 healthcare companies by revenue as of 2024-2025, primarily based on trailing twelve-month (TTM) and fiscal year 2024 revenue data from multiple sources:
Top 10 Healthcare Companies by Revenue

1. UnitedHealth Group Inc.
  • Revenue: Approximately $400 billion
  • Description: A leading health insurance company providing data analytics, consulting, and pharmacy care services.
  • Market Capitalisation: $275.8 billion (as of July 2025)
  • Market: NYSE, USA (1, 2, 4)
2. CVS Health Corp.
  • Revenue: Around $361 billion to $373 billion
  • Description: A major pharmacy benefits manager and health services provider.
  • Market Capitalisation: $81.9 billion (as of July 2025)
  • Market: NYSE, USA (1, 2, 4)
3. McKesson Corp.
  • Revenue: About $309 billion to $359 billion
  • Description: A global pharmaceutical distribution and healthcare services company.
  • Market: NYSE, USA (1, 2, 4)
4. Cencora (formerly AmerisourceBergen)
  • Revenue: Approximately $294 billion to $310 billion
  • Description: A pharmaceutical sourcing and distribution services company.
  • Market: NYSE, USA (2, 4)
5. Cardinal Health Inc.
  • Revenue: Around $220 billion to $227 billion
  • Description: Manufacturer and distributor of medical and laboratory products serving hospitals and clinics.
  • Market: NYSE, USA (1, 4)
6. Cigna Group
  • Revenue: About $204 billion to $247 billion
  • Description: Global health services company with clinics and healthcare facilities in over 30 countries.
  • Market: NYSE, USA (1, 4)
7. Elevance Health (formerly Anthem)
  • Revenue: Approximately $172 billion to $177 billion
  • Description: Offers health plans and clinical, behavioral, pharmacy, and complex-care products.
  • Market: NYSE, USA (1, 4)
8. Johnson & Johnson
  • 2024 revenue: $88.8 billion
  • 2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion
  • Market Capitalisation: $377.5 billion (as of July 2025)
  • Headquarters: New Brunswick, New Jersey
  • Johnson & Johnson has seen significant change in recent years, first with its consumer healthcare separation in the summer of 2023 and more recently with Stelara’s loss of exclusivity at the start of 2025. Through these developments—and even more now in the wake of them—the company has remained focused on its innovative drug business. Thanks to new approvals and future label expansions, the company has projected that its innovative medicines business can deliver annual growth of 5% to 7% from 2025 to 2030. Of J&J’s $88.8 billion in global sales last year, its innovative medicines group delivered annual sales of nearly $57 billion. Its medtech division, meanwhile, pulled down nearly $32 billion. Both groups delivered sales growth of 4% to 5% compared with 2023.
Related: Top 10 drugs losing US exclusivity in 2025

9. Roche Holding
  • 2024 revenue: USD $73.6 billion (60.5 billion Swiss francs)
  • 2025 First-Quarter reported sales growth of 6% to USD $18.7 Billion (CHF 15.4 billion)
  • Market Capitalisation: $258.7 billion (as of July 2025)
  • Headquarters: Basel, Switzerland
  • If one were to name 2024’s star pharmaceutical products beyond the GLP-1s, Roche’s eye injection Vabysmo would likely be on the list. First approved by the FDA in January 2022 as a competitor to Bayer and Regeneron’s Eylea, Vabysmo already reached 3.86 billion Swiss francs (about $4.5 billion) of sales in 2024. The rise of Vabysmo pushed the checkpoint inhibitor Tecentriq off Roche’s top three medicines list by sales.
10. Sinopharm Group
  • 2024 revenue: USD $80 billion.
  • 2025 First-Quarter reported sales: USD $19 billion (CNY $141 B)
  • Market Cap: $7.37 billion (USD)
  • Price-to-Sales (P/S) ratio: 7.37/73.9 = 0.1*
  • Sinopharm reported 2024 revenue of approximately $80 billion USD, ranking it second among the top pharmaceutical companies by revenue. However, its market capitalization stands at only about $7.37 billion USD, classifying it as a relatively small-cap company and indicating it is significantly undervalued based on its Price-to-Sales (P/S) ratio of roughly 0.1. This discrepancy suggests that Sinopharm’s stock price does not fully reflect its revenue-generating capacity, potentially due to market perceptions, regional factors, or other risks affecting investor confidence.
  • Full Name: Sinopharm Group Co., Ltd.
  • Listed on the Hong Kong Stock Exchange (HKEX) - Stock Code: 1099.HK
Market Capitalisation

As of July 2025, Eli Lilly’s market capitalization stands at approximately $749 billion, making it the largest healthcare company by market cap globally. Novo Nordisk’s market capitalization is about $317 billion, ranking it fourth among the top healthcare companies by market capitalization.

Related: Top 10 Healthcare Companies by Market Capitalisation

Price to Sales Ratio*

Eli Lilly
  • Price-to-Sales (P/S) ratio: 749/45 = 16.6
Novo Nordisk
  • Price-to-Sales (P/S) ratio: 317/42 = 7.5
Johnson & Johnson
  • Price-to-Sales (P/S) ratio: 377/89 = 4.2
UnitedHealth Group
  • Price-to-Sales (P/S) ratio: 276/400 = 0.7
*The result of dividing a company's market capitalization by its revenue is known as the Price-to-Sales (P/S) ratio or sales multiple. It indicates how much investors are willing to pay for each dollar of a company's sales. A lower P/S ratio may suggest a stock is undervalued, while a higher ratio could indicate overvaluation, though this depends on industry standards.

Disclaimer

The information presented in this article, "Top 10 Healthcare Companies by Revenue in 2025," is intended for general informational purposes only and should not be construed as professional financial, investment, or medical advice. The revenue figures, company rankings, and projections are based on publicly available data, company reports, and industry estimates as of 2025. All currency conversions, where applicable, are based on annual average exchange rates, and revenues outside the health sciences sector have been excluded for consistency (1).

While efforts have been made to ensure the accuracy and timeliness of the information, One Day Advisor and the article’s authors do not guarantee the completeness, reliability, or suitability of the content for any particular purpose. Readers are encouraged to verify details independently and consult qualified professionals before making any business, investment, or healthcare decisions based on the information provided.

The article may reference ongoing developments, regulatory actions, or market events that are subject to change. One Day Advisor is not responsible for any losses or damages arising from the use of this information.


Related:


Top 10 Pharmaceutical Companies by Revenue in 2025

Top 10 Drugs by Worldwide Sales in 2025

Comments

Post a Comment

Pages

Archive

Show more

Popular posts from this blog

Top 10 Stocks Poised to Outperform in August 2025: AI, Clean Energy, and Tech Leaders to Watch

By -
Image
As August 2025 unfolds, investors are eagerly seeking opportunities to capitalize on the market’s strongest performers. Driven by rapid advancements in artificial intelligence, the accelerating global energy transition, and robust demand for technology infrastructure, certain companies stand out as frontrunners poised for substantial growth. This article highlights the top 10 stocks expected to outperform in August 2025, providing insights into their recent momentum, sector leadership, and the key trends fueling their rise. Whether you’re looking to boost your portfolio with cutting-edge innovators or aiming for steady gains through resilient industries, these companies represent some of the most compelling investment prospects in the current market landscape. Based on recent trends and analyst forecasts for August 2025, the following companies are expected to outperform: 1. Nvidia (NVDA) NVIDIA (NVDA) is rated a "Strong Buy" by a consensus of analysts, with 44–64 analysts (d...
Read more

Top 10 ETF Picks for August 2025: Best Funds to Buy Now for Growth, Safety, and Diversification

By -
Image
Here are the top 10 ETF picks for August 2025, along with insights on whether they are worth considering for investment right now. This list blends global equity leaders, sector specialists in defense and metals, and broad market trackers—balancing momentum with diversification and risk management. Current market conditions and upcoming events like the U.S. Federal Reserve’s September meeting make August a timely opportunity to reallocate or accumulate: 1. SPDR S&P 500 ETF Trust (SPY) or Vanguard S&P 500 ETF (VOO) Broad U.S. equity exposure; strong performers with SPY up 8.9% YTD and focused on the AI rally and potential post-rate-cut growth ( 1 ,  2 ). Would buy: Yes, for long-term core holding and growth. 2. iShares Core S&P 500 ETF (IVV) Similar to SPY/VOO, highly liquid, low expense ratio. Would buy: Yes, for passive U.S. equity exposure ( 2 ). 3. VanEck Gold Miners ETF (GDX) or  DAXglobal Gold Miners Gold/silver miners are up 34%–68% YTD, fueled b...
Read more

Top August 2025 ETFs: In-Depth Performance Reviews

By -
Image
Here is an in-depth performance review of the top ETFs for August 2025, highlighting key trends, returns, and sector strengths to help investors understand current market dynamics and make informed decisions: 1. Gold Miners and Basic Materials ETFs Leading the Pack The best-performing ETFs so far in 2025 are heavily concentrated in gold miners and basic materials sectors. For example, the DAXglobal® Gold Miners ETF has delivered an exceptional 66.3% return this year, remaining the top performer in its category. The DAXglobal® Gold Miners index is tracked primarily by the L&G Gold Mining UCITS ETF, which is domiciled in Ireland and was launched on 15 September 2008. This ETF is listed on European exchanges including: XETRA (Germany) with the ticker symbol ETLX Stuttgart Stock Exchange (Germany) also listing the same ticker GDX  is the flagship US-listed gold miners ETF with large assets and active trading, holding major gold mining stocks like Newmont, Barrick Gold, and Fran...
Read more

Top XRP ETFs to Watch in 2025: Dominating Holdings, Low Fees, and Performance Insights

By -
Image
As the cryptocurrency market matures in 2025, XRP ETFs have emerged as essential instruments for investors seeking regulated and accessible exposure to this dynamic digital asset. With a growing variety of futures-based and physically backed spot ETFs now available across major markets like the U.S., Canada, and Europe, understanding the nuances of these products—including their fee structures, holdings, and performance—is crucial for making informed investment decisions. This article highlights the top XRP ETFs to watch in 2025, providing deep insights into their dominating holdings, low fees, and recent market impact, all organized in a clear list format for easy navigation. Whether you are a long-term investor or an active trader, this guide will help you identify opportunities and risks in the evolving XRP ETF landscape. 1. Leading XRP ETFs in 2025 ProShares Ultra XRP ETF (UXRP) Type: 2x leveraged futures-based ETF listed in the U.S. Launched: July 18, 2025 Key Features...
Read more

7 Best AI Automated Trading Software for 2025

By -
Image
The best AI automated trading software for 2025 includes a variety of sophisticated platforms designed for different trading needs and asset classes such as stocks, crypto, forex, and options. Leading options are: 1. Trade Ideas Primary Focus : Stock market trading (US equities) AI Engine : "Holly" runs millions of virtual trades nightly to discover new strategies with statistical edges. The system generates real-time signals and risk-managed trading ideas during market hours. Features : AI-generated trade ideas and risk ratings Backtesting capability for custom strategies Simulated (paper) and live trading integration Advanced scanning and alert functionalities Who Should Use : Retail and professional stock traders looking for actionable, AI-driven trade alerts with robust analysis. Pricing : Starts at $89/month, with free trial available. 2. TrendSpider Primary Focus : Technical analysis automation for stocks, ETFs, and forex. AI/Autom...
Read more

Top 10 Pharmaceutical Companies by Revenue in 2025 (July Edition)

By -
Image
Here are the top 10 pharmaceutical companies by revenue as of 2025, primarily based on first quarter 2025 revenue data. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 ,  2 ,  3 ). Aug 1, 2025 Update:  @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). While earnings and revenue reports are considered lagging indicator...
Read more

Top 10 Credit Cards for Hospital Bills in Singapore 2025

By Editorial Team -
Image
If you are looking for the best credit cards for hospital bills in Singapore , you've come to the right place. Whether you're dealing with big doctors' bills right now or regularly spend on your health, you may be interested in a credit card that offers rewards for medical spend. Most credit cards actively exclude hospital spend from earning rewards. So, to make things easier, the experts from Value Champion have scoured the terms & conditions of 100+ cards in Singapore to find which actually do provide cash rebates or miles. Earning Rewards on Hospital Bills & Why We Selected these Cards Medical bills, whether for a doctor or a hospital visit, can be quite expensive and are sometimes difficult to pay off all at once. Facing such a large bill can certainly be daunting, but doing so also presents the opportunity to earn significant cashback or miles (the greater the spend, the greater the return). Additionally, some credit cards offer 0% interest instalment plans wh...
Read more

Best Bitcoin ETFs of 2025: Should You Buy Today?

By -
Image
As of 2025, the Bitcoin ETF landscape is dominated by a mix of spot Bitcoin ETFs offering direct exposure to the cryptocurrency and Bitcoin futures strategy ETFs that provide exposure through futures contracts. The top Bitcoin ETFs expected to dominate based on holdings and fees reflect a balance between large assets under management (AUM), competitive expense ratios, and investor preferences for spot versus futures exposure. What Is a Spot Bitcoin ETF? Spot Bitcoin ETFs, which first began trading on U.S. exchanges Jan. 11, 2024, are exchange-traded funds that track the price of Bitcoin by directly holding the cryptocurrency itself, unlike the futures-based Bitcoin ETFs that have traded on exchanges since 2021. When an investor buys shares of a spot Bitcoin ETF, they are buying a portion of the Bitcoin held by the fund. Thus, a spot Bitcoin fund works in a similar way as a physically backed gold ETF . How to Choose the Best Spot Bitcoin ETF  Choosing the...
Read more

Did Steve Jobs Refuse Treatment for Pancreatic Cancer?

By Editorial Team -
Image
It’s been more than 12 years since the passing of Steve Jobs. Legendary Apple Inc., Co-founder Steve Jobs passed away at only 56 years old after battling pancreatic neuroendocrine tumor, a rare form of pancreatic cancer. A growing list of people in the public spotlight have faced pancreatic cancer, including tech innovators, entrepreneurs and influencers. In addition, and connected to Jobs, Jef Raskin, developer of the Macintosh computer, passed away of pancreatic cancer in 2005. And, coincidentally, Dag Kittlaus, creator of Siri, which was acquired by Apple in 2010, was diagnosed with the same exact cancer that took the life of Jobs. Pancreatic neuroendocrine tumors (or PNETs) account for less than 10% of all pancreatic cancer tumors and tend to grow slower than exocrine tumors, the most common type of pancreas tumors. Jobs survived eight years before dying of the disease on Oct. 5, 2011. The five-year survival rate for pancreatic cancer is only 10%. Since PNETs are so uncommon, trea...
Read more

Top 10 Pharma Companies by Market Cap in 2025

By -
Image
Here are the top 10 pharmaceutical companies by market cap as of July 2025. The pharmaceutical industry remains robust amid evolving market dynamics, driven by innovation, strategic expansions, and shifting healthcare policies. This mid-2025 update integrates the first half's (H1) financial results to provide readers with a clear snapshot of leading companies’ performance and trajectory. Aug 1, 2025 Update:  @POTUS  sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Credit: CompaniesMarketCap.com ...
Read more